CYP51-IN-33

CYP51-IN-33 (Compound F50) at 20 mg/L potently inhibits mycelial growth of Valsa mali, Sclerotinia sclerotiorum, Botrytis cinerea, Rhizoctonia solani, Alternaria alternata, Fusarium graminearum, Curvularia lunata, and Phytophthora capsici in vitro, with EC₅₀ values ranging from 0.01 to 0.77 mg/L^[1].
CYP51-IN-33 potently inhibits the CYP51 enzyme activity of Rhizoctonia solani in vitro, with an IC₅₀ value of 0.35 μM^[1].
CYP51-IN-33 (0.1 mg/L; 24 h) alters the transcriptome of Rhizoctonia solani, including the upregulation and downregulation of key genes in the ergosterol biosynthesis pathway^[1].
CYP51-IN-33 (0.1 mg/L) alters the mycelial morphology of Rhizoctonia solani, increases cell membrane permeability, and induces intracellular ROS accumulation^[1].
CYP51-IN-33 (0.1 mg/L) alters the metabolome of Rhizoctonia solani, causing dysregulation of membrane-related metabolic pathways, carbohydrate metabolic pathways, and cofactor metabolic pathways^[1].
CYP51-IN-33 at concentrations of 1.0-2.0 mg/L exerts only a slight effect on HepG2 cell viability even at the highest concentration of 2.0 mg/L^[1].
CYP51-IN-33 (1.0 or 2.0 mg/L) exerts minimal effects on the viability of HepG2 cells, with the proportions of viable cells reaching 94.24% and 93.83%, respectively, compared with 94.30% in the control group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.